+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Use of the yellow fever virus vaccine strain 17D for the study of strategies for the treatment of yellow fever virus infections



Use of the yellow fever virus vaccine strain 17D for the study of strategies for the treatment of yellow fever virus infections



Antiviral Research 30(2-3): 125-132



We have employed the attenuated vaccine strain 17D of yellow fever virus (YFV) to evaluate the inhibitory effect of a selected series of compounds on YFV in Vero cells. Use of the vaccine strain does not require high-level microbiological containment facilities and should allow extensive screening. In addition, YFV may serve as a model for other flaviviruses including hepatitis C virus (HCV), and thus strategies for the treatment of YFV infections may apply to flavivirus infections in general. In the present study, several compounds belonging to different classes of nucleoside analogues and polyanions were evaluated for their inhibitory effect on the replication of YFV. Compounds that are targeted at: (i) IMP dehydrogenase (ribavirin, EICAR, tiazofurin, selenazofurin and mycophenolic acid), (ii) OMP decarboxylase (pyrazofurin and 6-azauridine), (iii) CTP synthetase (carbodine and cyclopentenyl cytosine), (iv) dihydrofolate reductase (methotrexate) and the (v) sulfated polymers (dextran sulfate and PAVAS) proved inhibitory to the replication of YFV. Mycophenolic acid (EC50: 0.08 microgram/ml). EICAR (EC50: 0.8 microgram/ml) and methotrexate (EC50: 0.07 microgram/ml) were the most effective. The findings that EICAR and mycophenolic acid, despite their potent anti-YFV activity, had little or no effect on the replication of the bunyavirus Punta Toro or herpes simplex virus in Vero cells, indicates that their anti-YFV activity is rather specific and does not merely result from cytotoxicity. Inhibitors of S-adenosylhomocysteine hydrolase (SAH hydrolase) and thymidylate synthase were found to be devoid of anti-YFV activity.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 047901347

Download citation: RISBibTeXText

PMID: 8783804

DOI: 10.1016/0166-3542(96)89697-5


Related references

Neutralization tests with immune yellow fever sera and a strain of yellow fever virus adapted to mice. Ann Trop Med And Parasitol [Liverpool] 25(1): 69-77, 1931

Protection of mice against yellow fever virus encephalitis by immunization with a vaccinia virus recombinant encoding the yellow fever virus non-structural proteins, NS1, NS2a and NS2b. Journal of General Virology 71: 1697-1702, 1990

Travel characteristics and yellow fever vaccine usage among US Global TravEpiNet travelers visiting countries with risk of yellow fever virus transmission, 2009-2011. American Journal of Tropical Medicine and Hygiene 88(5): 954-961, 2013

Japanese encephalitis virus/yellow fever virus chimera is safe and confers full protection against yellow fever virus in intracerebrally challenged mice. Vaccine 36(18): 2450-2455, 2018

Immunological studies of group B arthropod-borne virus. V. Evaluation of cross-immunity against type 1 dengue fever in human subjects convalescent from sub clinical natural Japanese encephalitis virus infection and vaccinated with 17D strain yellow fever vaccine. Amer J Trop Med Hyg 15(4): 588-600, 1966

Rapid detection and quantification of RNA of Ebola and Marburg viruses, Lassa virus, Crimean-Congo hemorrhagic fever virus, Rift Valley fever virus, dengue virus, and yellow fever virus by real-time reverse transcription-PCR. Journal of Clinical Microbiology 40(7): 2323-2330, 2002

Completed sequences analysis on the Chinese attenuated yellow fever 17D vaccine strain and the WHO standard yellow fever 17D vaccine strain. Zhongguo Yi Miao he Mian Yi 15(2): 145-151, 2009

Comparison of the nucleotide and deduced amino acid sequences of the structural protein genes of the yellow fever 17DD vaccine strain from Senegal with those of other yellow fever vaccine viruses. Vaccine 11(6): 679-681, 1993

Genetic relationships and evolution of genotypes of yellow fever virus and other members of the yellow fever virus group within the Flavivirus genus based on the 3' noncoding region. Journal of Virology 78(18): 9652-9665, 2004

Recombinant vaccinia virus producing the prM and E proteins of yellow fever virus protects mice from lethal yellow fever encephalitis. Virology 187(1): 290-297, 1992

Use of the yellow fever virus vaccine strain 17D as a model to investigate hepatitis C virus inactivation efficacy in gastrointestinal endoscopy. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 40: 274, 2000

Immunological studies with Group B arthropod-borne viruses. IV. Persistence of yellow fever antibodies following vaccination with 17D strain yellow fever vaccine. Amer Jour Trop Med And Hyg 12(2): 230-235, 1962

Immunological studies with group B arthropod-borne viruses. IV. Persistence of yellow fever antibodies following vaccination with 17D strain yellow fever vaccine. American Journal of Tropical Medicine and Hygiene 12: 230-235, 1963

Cross immunization and neutralization between the neurotropic virus of classical yellow fever and of the sylvan yellow fever virus. Bol Inst Hig Sao Paulo 18, 1943

Yellow fever virus/dengue-2 virus and yellow fever virus/dengue-4 virus chimeras: Biological characterization, immunogenicity, and protection against dengue encephalitis in the mouse model. Journal of Virology 77(6): 3655-3668, 2003